Fresenius Kabi Polska sp. z o.o.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2001-06-27
Share capital
27,130,000.00 PLN
Activity description

Fresenius Kabi Polska specializes in lifesaving medicines and technologies for critically and chronically ill patients across biopharma, medtech, nutrition and pharma. The company also develops blood donation systems with MDR Class III CE certification and supports care for patients throughout the breast cancer journey.

Registered address
Aleje Jerozolimskie 134, 02-305 Warszawa, Poland
Email
Social media
Electronic delivery address
AE:PL-67724-36747-WHBVA-19

Financials

Revenue history (in m)

From the notes

Current income tax (CIT due)$8,354,596

Filing timeliness

1 of 6 financial statements was filed late (for 2021, 84 days late). All were audited by a statutory auditor.

  • 202508/07/2026
  • 202408/07/2025
  • 202309/07/2024
  • 202204/07/2023
  • 202107/10/2022
  • 202015/10/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Sector · Manufacturing289 / 24,548
Top 1.2%
City · Warszawa272 / 56,729
Top <1%
Voivodeship · Mazowieckie339 / 76,892
Top <1%
Country · Poland873 / 297,069
Top <1%

Results vs industry

Revenue
This companyUSD 247.10mMedianUSD 913.43kAverageUSD 25.82m
Net profit
This companyUSD 33.38mMedianUSD 14.22kAverageUSD 2.77m
Operating costs
This companyUSD 198.98mMedianUSD 846.99kAverageUSD 21.42m
Assets
This companyUSD 236.96mMedianUSD 897.46kAverageUSD 31.52m

Offer

Certifications: ISO 9001

Websites

The sites are available in: English and German.

Public procurement

1891 tenders recorded as contractor: 499 national ($21,502,549) and 1392 EU ($983,283,659).

SubjectAmount
Dostawa pojemników potrójnych góra-dół do pobierania i preparatyki krwi.
–
Supply of medicines, lots 1–41
–
Supply of single-use medical equipment
$40,003

Trademarks

The company holds 8 active trademarks registered with the Polish Patent Office. 10 marks have expired or were not registered. The first mark was filed in 1995.

MarkNumberClassesStatusProtected until
żywienie ma znaczenie Z.57539044Protected Oct 11, 2034
żywienie ma znaczenie Z.5748709, 38, 41, 42Protected Sep 24, 2034
mój Fresubin Z.5748695, 10, 35Protected Sep 24, 2034
MOC PŁYNOTERAPII Z.49256916, 41Protected Nov 13, 2028
ŻYCIE W PŁYNIE Z.4801335Protected Dec 14, 2027
MarkProtected until
żywienie ma znaczenie Oct 11, 2034
żywienie ma znaczenie Sep 24, 2034
mój Fresubin Sep 24, 2034
MOC PŁYNOTERAPII Nov 13, 2028
ŻYCIE W PŁYNIE Dec 14, 2027

Job offers

The company has its own careers page: fresenius-kabi.com/work-with-us.

Authorized Representatives

Magdalena Aleksandra Przygodzka age 49 – Attorney-in-fact (joint)
Linda Franičević – President of the Management Board
Izabella Grabska age 53 – Attorney-in-fact (joint)
Tomasz Michał Halik age 49 – Management Board Member

Manner of representation

In the case of a multi-member management board, two members of the management board jointly or one member of the management board jointly with a commercial proxy.

Ownership

OwnerSharesShare valueStake
Fresenius Kabi Ag
54,260$7,328,471.10100%

Beneficial owners

Person

Capital group

The company belongs to the Fresenius SE & Co. KGaA (Germany) group, which is its direct owner. The group has 95 companies, 90 of them abroad.

NameCountry
Clinico MedicalPoland
Fresenius Digital Technology PolskaPoland
Fresenius Kabi Business ServicesPoland
Audere Medical Services LimitedUnited Kingdom
Avensys UK Group LimitedUnited Kingdom

Bank accounts

Registered as a VAT taxpayer on 2003-11-30.

Debt

No entries in the National Debtors Register (KRZ).

Real estate

TypeAmount
Land (incl. perpetual usufruct)
$867.7K
Buildings and premises
$22.3M

MSiG notices

Publication dateEvent
Jul 22, 2026Return of additional payments
Feb 28, 2014Merger plan
May 6, 2013Merger plan

Public aid

PurposeGross amount
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
–
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
–

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Adamed Pharma S.A.
Teva Operations Poland sp. z o.o.
Zentiva Polska sp. z o.o.
Przedsiębiorstwo Produkcji Farmaceutycznej Hasco - Lek S.A.
Tarchomińskie Zakłady Farmaceutyczne Polfa S.A.
Przedsiębiorstwo Farmaceutyczne Lek-Am sp. z o.o.
Farmak International sp. z o.o.
Sandoz Polska sp. z o.o.
Synoptis Pharma sp. z o.o.
Bioton S.A.

Change history

DateEvent
2018-12-06Address change
2015-12-02Address change
2012-11-27Share capital increase
2009-09-07Share capital increase
2005-06-07Address change

FAQ

Last updated: 2026-10-29